Privacy Policy
Signals Blog

Contributors

Categories

Right Turn: From chemistry to biology: A plastic cell

. My colleague, Casandra Gardner, PhD, was excited when she came across the image, below, of a plastic cell. Since my understanding of polymers is limited to what my university chem-eng boyfriend taught me many (many!) years ago, I thought Casey would do a much better...

The scientific pursuit of eternal youth

> “I resolve to not get any older.” This may seem like a somewhat outlandish New Year’s resolution, a desire more grounded in the realm of science fiction than science itself. But a growing group working in the field of biogerontology would argue that it is...

Right Turn: Revenge of the Somatic

> If you’ve ever wondered what makes a stem cell hasten its way down the mutational road to cancer, wonder no more. The answer is revenge – a kind of adolescent rebellion against parental (the body’s) and evoloutionary control. At least...

Breaking out of our scientific cells

> I have recently been transitioning from “basic” science research to science communication. Why? Because there is a great disparity in what the public, policy makers, and even clinicians, know and think about research, and what the researchers know. I believe as...

Regenerative Medicine Deal Review: December

. Welcome to your Regenerative Medicine Deal Review for the month of December. Toronto-based Stem Cell Therapeutics successfully executed on a financing of $33 million, while Pluristem announces it is moving forward on a licensing agreement with Korea-based CHA....

Right Turn: Some views on drug discovery

> Earlier this week, we tweeted some articles published online at Scientific American that provide some perspectives on the complexity and high costs of drug discovery – so far, two have been published, here and here. The tweet elicited a thought-provoking...

Update from the Clinic: December

. Welcome to your Update from the Clinic for the month of December. Athersys and NeoStem both confirm completion of enrollment for phase 2 studies while bluebird bio announces the first patient transplanted in its phase 1/2 study of HGB-205 in patients with...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!